6:29 PM · 23 April 2020

BREAKING : Strong declines on Wall Street - Gilead drug rejected in phase I testing

In the last minutes we have been observing a strong declines on Wall Street. This is linked to recent rumors that a Gilead drug called Remdesivir, which showed the most promising initial results in the treatment of  coronavirus, was rejected in phase I tests. S&P 500 retreats from around 2830 points, below 2790 points. Gilead's stock is currently losing 2%. This information was provided by the Financial Times.
S&P 500 dropped sharpy lower after information regarding coronavirus drug hit the markets. Source: xStation5
18 September 2026, 6:36 PM

What could halt the uptrend❓

18 September 2026, 12:11 PM

Market warp: Rate Forecasts and Semiconductors in the Spotlight

18 September 2026, 6:30 AM

📊Morning Briefing: BoJ raises rates, but the yen paradoxically weakens (18.09.2026)

17 September 2026, 7:17 PM

Daily Summary: Hawkish Fed fails to scare the markets (17.09.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits